Learn about ACTEMRA® treatment for rheumatoid arthritis, giant cell arteritis, systemic juvenile idiopathic arthritis, and polyarticular juvenile idiopathic arthritis. Find instructions for ACTEMRA® (tocilizumab) subcutaneous injections and helpful information on the ACTEMRA® Medication Guide that should help you better. Inside this kit you’ll also find: .. Some patients may be eligible for free drug through the .. Use a quick, dart-like motion to insert the needle all the way into.
|Published (Last):||11 August 2014|
|PDF File Size:||1.62 Mb|
|ePub File Size:||3.61 Mb|
|Price:||Free* [*Free Regsitration Required]|
Subcutaneous Injections for RA | ACTEMRA® (tocilizumab)
You may also report side effects to Genentech at Your healthcare provider should do blood tests to check your cholesterol levels 4 to 8 weeks after you start receiving ACTEMRA, and then every 6 months after that You should not receive ACTEMRA if your neutrophil and platelet counts are too low or your liver insett test xctemra are too high.
Your email has been sent! You may also call Genentech at Contact immediately, as well as your healthcare provider or nurse, if you experience any of these reactions:. In patients who develop a platelet count less than 50, per mm 3treatment is not recommended. Tell your healthcare provider right away if you see any signs of these symptoms:.
Reporting side effects Tell your healthcare provider right away if you are experiencing any side effects. Some people have died from these infections.
Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites. Patients should be closely monitored for the development of signs and symptoms of infection during and after treatment with ACTEMRA, including the inesrt development of tuberculosis in patients who tested negative for latent tuberculosis infection prior to initiating therapy.
Upper respiratory tract infections like common cold and sinus infections.
Patient Education and Training
ACTEMRA is an immunosuppressant, and treatment with immunosuppressants may result in an increased risk of malignancies. Patients with invasive fungal infections may present with disseminated, rather than localized, disease. This happens most often in people who also take nonsteroidal anti-inflammatory drugs NSAIDscorticosteroids, or methotrexate.
Events of gastrointestinal GI perforation have been reported in clinical trials, primarily as complications of diverticulitis in RA patients. Dosage modifications may be required.
The rate of serious infections was 9. Serious allergic reactions Serious allergic reactions, including death, can happen with ACTEMRA infusions or injections, even if they did not occur with an earlier infusion or injection. Some people have died from these infections. You should not do both.
Talking to your doctor Make the most of your office visit with this helpful guide. Tell your healthcare inseet if you have these or any other side effect that bothers you or does not go away: The most commonly reported serious infections included pneumonia, gastroenteritis, varicella, and otitis media. Infection signs, with or without a fever, include: If you packzge systemic juvenile idiopathic arthritis SJIA you will have blood tests done every 2 to 4 weeks during treatment.
Your healthcare provider should test you for hepatitis B before starting treatment. You should not do both. Some people have serious infections while packahe ACTEMRA, including tuberculosis TBand infections caused by bacteria, fungi, or viruses that can spread throughout the body.
Reviewing the Medication Guide should help you to better understand the risks and benefits of your RA treatment.
If packge have systemic juvenile idiopathic arthritis SJIA you will have blood tests done every 2 to 4 weeks during treatment. An infection, think you may have an infection, are being treated for an infection, or get a lot of infections that return. Your email has been sent!
If you had hives, actemta rash, or experienced flushing after injecting, you should tell your healthcare provider or nurse before your next injection. The risks and benefits of treatment with ACTEMRA should be carefully considered prior to initiating therapy in patients with chronic or recurrent infection.
Demyelinating Disorders The impact of treatment with ACTEMRA on demyelinating disorders is not known, but multiple sclerosis and chronic inflammatory demyelinating polyneuropathy were reported rarely in clinical studies.